By Fineline Cube 
Danaher Corporation (NYSE: DHR) reported first-quarter 2026 revenues of $6.0 billion, up 3.5% year-over-year, with net earnings of $1.0 billion, while announcing its intention to acquire Masimo Corporation, a leader in acute care patient monitoring solutions.
Financial Performance & Segment Highlights
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Global Revenues | $6.0 billion | +3.5% |
| Net Earnings | $1.0 billion | — |
| Bioprocessing Segment | Strong performance | Outperformed expectations |
| Life Sciences Segment | Better-than-expected results | Positive contribution |
| Cepheid | Weaker performance | Partially offset by other segments |
The company’s diversified portfolio demonstrated resilience, with exceptional strength in Bioprocessing and Life Sciences effectively counterbalancing Cepheid’s underperformance during the quarter.
Strategic Acquisition: Masimo Corporation
Danaher announced plans to acquire Masimo Corporation, a premier provider of:
- Mission-critical pulse oximetry solutions
- Advanced patient monitoring systems for acute care settings
This strategic move aligns with Danaher’s disciplined portfolio management approach and is expected to strengthen its position in the high-growth healthcare technology sector.
Updated Full-Year Guidance
Based on strong first-quarter results and improved outlook across key business segments, Danaher has raised its full-year 2026 guidance:
| Metric | Updated Guidance |
|---|---|
| Non-GAAP Core Revenue Growth | 3% to 6% YoY |
| Adjusted Diluted EPS | $8.35 to $8.55 per share |
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, acquisitions, and guidance. Actual results may differ based on market conditions, integration success, and regulatory approvals.-Fineline Info & Tech